Interim report January-March 2018

Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the first quarter 2018.

IMPORTANT EVENTS DURING THE FIRST QUARTER

  • In February, Vicore Pharma Holding acquired additional shares from an existing shareholder in I-Tech. As such, our holding amounted to 26.5%. In March, I-Tech issued shares to a new shareholder, Cambrex Karlskoga AB. Vicore Pharma Holding’s holding is consequently 21.2%.

IMPORTANT EVENTS AFTER THE PERIOD

  • In April Vicore Pharma holds approval from the UK authorities and the Ethics Committee to initiate a Phase IIa Study on Idiopathic Pulmonary Fibrosis (IPF)

FINANCIAL SUMMARY (GROUP)

KSEK  Jan-Mar 2018  Jan-Mar 2017  Year
2017 
Year
2016 
Operating profit/loss  -4 235  -2 456  -12 793   -6 649 
Profit/loss after financial items  4 257  -2 514  -12 855  -6 652 
Earnings per share, SEK  0,27  -0,16  -0,81  -0,54 
Equity as per end of period  117 226  101 928   112 969   75 597  
Cash flow from operating activities  -2 261  -2 474   -7 703   -7 289  
Cash flow from investing activities  -7 649  -3 613   -22 780   -13 940  
Cash and cash equivalents as of end of period  13 744  27 024   24 019   4 266  

For more information, please contact:

Hans Jeppsson, CFO
M: +46 (0)70 553 14 65

hans.jeppsson@vicorepharma.com

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 09.00 CET on May 8, 2018

About Vicore Pharma Holding

Vicore Pharma AB develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and USA. In addition, C21 is explored pre-clinically for a number of diseases where the AT2 receptor plays an important role. I-Tech AB is an associated company to Vicore Pharma Holding. The company has developed and commercialized Selektope® , an effective chemical agent used as an antifouling ingredient in antifouling paints. The companies are based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, please refer to www.vicorepharma.com

Tags:

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Documents & Links